Published in final edited form as:

Curr Top Behav Neurosci. 2020 ; 45: 101–121. doi:10.1007/7854_2020_134.

Nicotinic Receptors Underlying Nicotine Dependence: Evidence from Transgenic Mouse Models

Cassandra D. Gipson¹, Christie D. Fowler²

¹Department of Psychology, Arizona State University, Tempe, AZ, USA

²Department of Neurobiology and Behavior, University of California, Irvine, CA, USA

Abstract

Nicotine underlies the reinforcing properties of tobacco cigarettes and e-cigarettes. After inhalation and absorption, nicotine binds to various nicotinic acetylcholine receptor (nAChR) subtypes localized on the pre- and post-synaptic membranes of cells, which subsequently leads to the modulation of cellular function and neurotransmitter signaling. In this chapter, we begin by briefly reviewing the current understanding of nicotine's actions on nAChRs and highlight considerations regarding nAChR subtype localization and pharmacodynamics. Thereafter, we discuss the seminal discoveries derived from genetically modified mouse models, which have greatly contributed to our understanding of nicotine's effects on the reward-related mesolimbic pathway and the aversion-related habenulo-interpeduncular pathway. Thereafter, emerging areas of research focusing on modulation of nAChR expression and/or function are considered.

Taken together, these discoveries have provided a foundational understanding of various genetic, neurobiological and behavioral factors underlying the motivation to use nicotine and related dependence processes, which are thereby advancing drug discovery efforts to promote long-term abstinence.

Introduction

Nicotine is the primary active constituent in tobacco-containing products, which is responsible for maintaining smoking behavior in humans (Stolerman and Jarvis 1995). Recently, nicotine has also been formulated for vapor inhalation via e-cigarettes devices (Electronic Nicotine Delivery Systems, or ENDS; (St Helen et al. 2016)). Concomitant with a decrease in combustible tobacco cigarette use, use of e-cigarettes, especially among adolescents, has drastically risen in recent years (Wang et al. 2018). Indeed, from 2017–2018, there was a rapid increase in vaping prevalence among adolescents aged ~13–18 years old, with nicotine vaping rates translating to roughly an additional 1.3 million adolescent users in 2018 compared to 2017 (Miech et al. 2019). Although e-cigarettes may have value as a nicotine replacement strategy for current tobacco smokers (Hajek et al. 2019), the increasing patterns of e-cigarette use among adolescents has become of high concern and warrants further investigation. As well, among current smokers, some studies show that e-cigarettes are not liked as much as tobacco cigarettes (Strasser et al. 2016), and therefore, additional research is needed to determine the ability of e-cigarettes to accomplish nicotine replacement, harm reduction, or act as a quit aid (Rennie et al. 2016; Selya et al. 2018).

Chronic exposure to nicotine or nicotine-containing products is associated with detrimental health effects, including enhanced brain injury and/or stroke risk (Sifat et al. 2018), altered blood brain barrier permeability (Hawkins et al. 2004), promotion of tumor growth via nicotine and its carcinogenic metabolites cotinine, N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; (Ginzkey et al. 2013; Ginzkey et al. 2012; Jacob et al. 2009; Nakada et al. 2012), early onset of menopause in women (Bellavia et al. 2016), among others. Of importance, recent research has found that e-cigarette smoke may be carcinogenic and lead to increased risk of lung and bladder cancer, as well as heart disease, due to DNA damage (Lee et al. 2018). Given the harmful health effects associated with chronic use of nicotine-containing products, understanding the mechanisms that drive nicotine use is essential.

Nicotine is an agonist at nicotinic acetylcholine receptors (nAChRs), the structure and function of which were discovered in the early 1980s using ligand-binding assays (Clarke et al. 1985; Patrick and Stallcup 1977). The nAChRs are members of a large family of cys-loop homologous receptors, which also includes muscle acetylcholine receptors (mAChRs), GABAA/C, glycine, and serotonin type 3 receptors (Miller and Smart 2010). The nAChRs are pentameric ion channels, whereby either homomeric or heteromeric subunits combine together to form a central pore (Zoli et al. 2015). The subunit composition and stoichiometry of nAChRs determine its unique pharmacological binding profile, as well as its susceptibility to desensitization (Picciotto et al. 2008).

Decades of research has uncovered important neural mechanisms that drive nicotine self-administration behavior. Specifically, nicotine engenders self-administration through activation of high affinity $\beta 2$ subunit-containing (denoted $\beta 2^*$) nAChRs localized on dopamine-containing cell bodies within the ventral tegmental area (VTA; (Klink et al. 2001; Picciotto et al. 1998)), and by altering glutamatergic and GABAergic tone in the VTA (Mansvelder et al. 2002). The net result of nicotine-induced activation of nAChRs is increased levels of extracellular dopamine within the nucleus accumbens (NAc; (Pontieri et al. 1996)), which is hypothesized to contribute to its reinforcing effects. Although activation of nAChRs can lead to motivated behavior, it is also through desensitization/inactivation that nAChRs can alter acetylcholine signaling and neuronal function (Colombo et al. 2013), which may also contribute to modulation of nicotine-motivated behavior. Importantly, both acetylcholine and nicotine lead to nAChR desensitization; however, nicotine leads to prolonged inactivation of these receptors, with a slower rate of recovery than the endogenous ligand (Giniatullin et al. 2005). Interestingly, $\alpha 4\beta 2$ nAChR desensitization occurs following cigarette smoking, which is correlated with reductions in cigarette craving (Brody et al. 2006).

It is important to note that nAChRs are expressed neuronally, on both pre- and post-synaptic terminals as well as on post-synaptic somatodendrites (Albuquerque et al. 2009). Additionally, some nAChRs (e.g., homomeric $\alpha 7$) are localized on astrocytes and microglia in the brain (Graham et al. 2003; Jensen et al. 1997; Noda and Kobayashi 2017; Shen and Yakel 2012; Shytle et al. 2004), which have important functions at glutamatergic neuronal synapses that impact synaptic plasticity (Wang et al. 2013). Subunit composition of nAChRs in the brain can vary depending on region and cell-type specific localization, the topography

of which continues to be studied (Gaimarri et al. 2007; Gotti et al. 2006; Hendrickson et al. 2013), and is important in understanding neurobehavioral processes modulated by nAChRs.

In this chapter, we describe the current state of the knowledge regarding nAChR subtype expression in a brain region- and pathway-specific manner as it relates to nicotine dependence and comorbid pathologies. To accomplish this goal, we address current tools in the field that have allowed for exploration of the role of nAChR function and expression in addiction-related processes, with a focus on findings garnered from transgenic mouse models. As well, we illuminate novel areas of research focusing on modulating nAChR expression and/or function, which may have important implications for nicotine dependence processes. Given the evolving landscape of nicotine-containing product use (Fowler et al. 2017), a better understanding of the neural processes underlying the motivation to use nicotine is needed to enhance drug discovery efforts to promote cessation from nicotine-containing products.

nAChR Function and Signaling

As noted above, the nAChR receptor composition plays an important role in response to pharmacological agents. When an agonist (e.g., acetylcholine or nicotine) is bound to nAChRs, the receptors are first activated and then can desensitize, followed by recovery once the agonist is unbound. The EC₅₀ value, which represents nAChR activation for the concentration of agonist producing half-maximal response amplitude, varies based on subunit composition. For example, the acetylcholine EC₅₀ value is 513 for rat $\alpha 7$ (Papke and Porter Papke 2002), but is 14 for rat $\alpha 3\beta 4$ (Bohler et al. 2001). Conversely, the measure for desensitization, or the concentration of agonist required to reduce the amplitude of the response by 50%, is termed the IC₅₀. Based on subunit composition, desensitization-induced inhibition of receptors can vary when activated by the same agonist; for instance, the rat $\alpha 4\beta 2$ IC₅₀ with nicotine is <0.01 (Paradiso and Steinbach 2003), whereas rat $\alpha 7$ is 1.3 (Fenster et al. 1997; Giniatullin et al. 2005). These values represent different rates of activation and inhibition, which have profound effects on nAChR modulation of neuronal function. It should be noted that the same receptor subtype can desensitize at different rates based on the agonist present. For example, rat $\alpha 7$ IC₅₀ value is 1.3 for nicotine, but is >10,000 for acetylcholine (Fenster et al. 1997; Papke and Porter Papke 2002). This is important because recovery rates are dependent upon the agonist present, with recovery rate from nicotine taking longer than acetylcholine in some cases (e.g., $\alpha 4\beta 2$; (Paradiso and Steinbach 2003)). Given the important role of nAChR subtypes such as $\alpha 4\beta 2$ in the reinforcing effects of nicotine (Changeux et al. 1998) and in modulating dopamine release (Mansvelder and McGehee 2002), different rates of desensitization and recovery of different nAChRs likely play key roles in the neural circuitry underlying nicotine addiction.

There are generally two binding sites for neuronal heteromeric nAChRs, each of which is formed by a pocket between subunits extracellularly at the ligand-binding N-terminal domain (Karlín 2002; Sine et al. 2002). Neuronally, $\alpha 7$ nAChRs are mainly homomeric and have five potential binding sites between the α subunits (Drisdel and Green 2000). Recently, additional binding sites for heteromeric nAChRs have been identified which are dependent on subunit composition (Jain et al. 2016). When a ligand is bound, the channel

opens within microseconds (Albuquerque et al. 2009), indicative of the rapid responsivity of these channels. A sequence of events occurs to alter the conformational state of the channel in order to open. Through computer generated modeling, it has been determined that when acetylcholine or nicotine is bound, hydrogen bonds among amino acids rearrange near the binding pocket. Subsequently, the C-loop moves toward the central pore, which then allows the Cys-Cys pair to interact with the bound ligand and results in the ligand being trapped deep within the pore between the subunits (Gao et al. 2005; Hansen et al. 2005).

As mentioned above, neuronal nAChRs can be expressed somatodendritically, pre-synaptically, or post-synaptically (Broide and Leslie 1999; McGehee et al. 1995; Wonnacott 1997). Nicotine binds to nAChRs located in the brain, which have identified subunits of $\alpha 2$ –7, and $\beta 2$ –4 (Boulter et al. 1987; Couturier et al. 1990; Picciotto et al. 2008). Somatodendritically-expressed nAChRs play a modulatory role in the neurotransmission of other systems in response to nicotine (Wonnacott et al. 2006), such as dopamine (Nisell et al. 1994). nAChRs that are expressed somatodendritically and modulate dopamine release appear to contain $\alpha 6$ and $\beta 3$ subunits, and differ in pharmacological response to nicotine and epibatidine compared to those expressed on terminals in the striatum (Reuben et al. 2000). Presynaptic nAChRs are also important in modulating neurotransmitter release. For instance, $\alpha 7$ nAChRs are Ca^{2+} -permeable, rapidly desensitize following activation and are expressed on many cell types including at glutamatergic terminals in brain regions such as the hippocampus and NAc (Fabian-Fine et al. 2001; Kaiser and Wonnacott 2000). Thus, nAChRs can enhance release of neurotransmitters from synaptic terminals, and may provide a feedforward mechanism by which cholinergic signaling gates neurotransmitter release. Post-synaptically, nAChRs modulate many functions within the brain, including the flow of auditory information in the thalamus. Specifically, $\beta 2$ -containing heteromeric nAChRs are located on neurons within the medial geniculate body receive cholinergic input from the pontomesencephalic tegmentum, and these receptors undergo an age-related decline in their expression and function (Sottile et al. 2017). As well, postsynaptic nAChR subunits such as $\alpha 6$, $\alpha 7$, $\beta 2$, and/or $\beta 4$ within the laterodorsal tegmentum, undergo changes in subunit composition due to age, which results in differential nicotine-induced neuronal excitability (Christensen and Kohlmeier 2016; Kaneda 2017; Kaneda et al. 2016; Shinohara et al. 2014; Taoka et al. 2016).

For decades, research has shown that chronic exposure to nicotine significantly alters expression and function of neuronal nAChRs (Fenster et al. 1999a; Fenster et al. 1999b; Gentry and Lukas 2002; Quick and Lester 2002). One nAChR subunit heavily involved in nicotine-induced striatal dopamine release and nicotine self-administration behavior, $\beta 2$ (see a more thorough description below), is upregulated and desensitized after chronic nicotine exposure, as measured via binding assays in intact oocytes (Fenster et al. 1999b). Following chronic activation due to nicotine, different subunit-containing nAChRs appear to desensitize at different rates, which is thought to underlie their ability to modulate different neurotransmitter systems. Further, changes in receptor expression with chronic nicotine appears to be cell type and nAChR subtype dependent (Benwell et al. 1988; Lallai et al. 2019; Marks et al. 1992; Perry et al. 1999). Both neuronal and non-neuronal cholinergic signaling involves some of the same subtypes of nAChRs and are associated with pathologies such as lung cancer (Mucchietto et al. 2016). One such subunit is $\alpha 5$,

which is expressed in non-neuronal tissues (Chini et al. 1992) such as lung, pancreas, stomach, and gliomas (Jia et al. 2016; Yoshikawa et al. 2005; Zia et al. 1997), and may mediate nicotine-induced lung cancer cell proliferation (Ma et al. 2014; Sun and Ma 2015). This subunit forms functional complexes with $\alpha 4\beta 2$ or $\alpha 3\beta 4$ subunits, and polymorphism of the human $\alpha 5$ gene, *CHRNA5*, is associated with nicotine dependence and lung cancer (Bierut et al. 2008; Chen et al. 2009; Saccone et al. 2009; Saccone et al. 2007). Importantly, the variant of $\alpha 5$, characterized by a change in the 398th amino acid from aspartic acid to asparagine (D398N), has been associated with a reduction in the function of the human $\alpha 3\beta 4\alpha 5$ nAChR (George et al. 2012), which has important implications for smoking cessation outcomes as well as other health pathologies.

nAChRs Mediating Nicotine Reinforcement

Genetically modified mouse models have allowed for the interrogation of receptors and circuits underlying complex behaviors. In the tobacco and nicotine field, groundbreaking studies by Picciotto, Changeux and colleagues (Picciotto et al. 1995; Picciotto et al. 1998) have provided an important foundation for the further progression of these animal models. Beginning with knockout mice, subsequent approaches have incorporated various genetic and technical tools to achieve more select manipulation of target protein or neurotransmitter function. These advances include, but are not limited to, humanized knockin genes, modified receptors, cre driver lines with floxed viral approaches, optogenetic and chemogenetic expression of receptors in a cell type specific manner, promoter driven fluorescent reporter lines, and most recently, CRISPR-Cas9 directed genetic modifications. Findings derived thus far from such approaches within each circuit are discussed in the following paragraphs.

Mesolimbic Pathway

The positive rewarding effects of nicotine involve the brain's mesolimbic pathway (Kenny and Markou 2005; Rice and Cragg 2004), consisting of dopaminergic projections from the VTA. The VTA integrating circuits and projection regions contain various nAChR subtypes expressed on dopaminergic, glutamatergic and GABAergic neurons (Charpantier et al. 1998; Klink et al. 2001; Mameli-Engvall et al. 2006; Mansvelder and McGehee 2002). For instance, inhibitory GABAergic projections from the rostromedial tegmental nucleus (RMTg) express terminal $\alpha 4\beta 2^*$ nAChRs. VTA dopaminergic cells projecting to both the NAc and prefrontal cortex (PFC) express $\alpha 4\alpha 6\beta 2$, $\alpha 4\beta 2$, and $\alpha 6\beta 2$ nAChRs, allowing for regulation of dopamine signaling through either somatic or presynaptic expression. These VTA dopaminergic neurons may also co-express glutamate or GABA, and it has been recently shown that heteromeric nAChRs mediate excitatory signaling in the dopaminergic-glutamate co-expressing cells (Yan et al. 2018). Within the NAc, the dopaminergic terminal nAChRs become activated by cholinergic interneurons and modulate dopamine's activation of GABAergic medium spiny neurons expressing dopamine D1 or D2 receptors. Intra-VTA glutamatergic circuits also appear to modulate GABAergic signaling via axoaxonic connections onto RMTg terminals. Further, glutamatergic projections from other brain regions, such as the PFC and subiculum, express presynaptic $\alpha 7$ nAChRs and have been found to terminate on the soma of dopaminergic neurons. Moreover, expression of the $\alpha 2$, $\alpha 5$ and $\beta 3$ nAChR subunits have also been localized within the VTA. Together, this

complicated pattern of nAChR expression makes defining the specific subtype contribution to nicotine reward and reinforcement challenging. However, significant advances have been made in this regard.

Initial studies in knockout mice have supported pharmacological findings implicating nAChRs expressing the $\beta 2$ nAChR subunit in mediating reward- and reinforcement-related processes. In the striatum, nicotine application induces a robust increase in dopamine release, which can be blocked by administration of the nAChR antagonist mecamylamine (Mifsud et al. 1989). However, this nicotine-mediated increase in dopamine release was absent in the striatum of mice lacking the $\beta 2$ nAChR subunit (Picciotto et al. 1998). To examine the involvement of this subunit on nicotine reinforcement, mice were assessed in an intravenous nicotine self-administration protocol, a technique with high translational validity to patterns of nicotine consumption in humans. Interestingly, while the wildtype mice exhibited sustained nicotine self-administration behavior, the $\beta 2$ knockout mice did not self-administer nicotine (Picciotto et al. 1998). A further study revealed similar findings with a lack of sustained self-administration behavior in the absence of the $\beta 2$ nAChR subunit with nicotine infusions directly into the VTA (Maskos et al. 2005). More recently, viral mediated re-expression of the $\beta 2$ nAChR subunit in the VTA of the knockout mice was shown to ‘rescue’ the behavioral phenotype, in which this site-specific re-expression led to the mice acquiring nicotine self-administration (Orejarena et al. 2012). Additional support from studies with $\beta 2$ knockout mice demonstrate that the $\beta 2^*$ nAChR is necessary for the formation of a conditioned place preference to a nicotine-paired environment and the discriminative stimulus properties of nicotine (Shoaib et al. 2002; Walters et al. 2006). In a cutting edge approach, Mourot and colleagues used a viral technique to express light-controllable $\beta 2^*$ nAChRs in the VTA, and during light exposure, the VTA $\beta 2^*$ nAChRs became inhibited, which thereby was sufficient to prevent the formation of a nicotine-induced conditioned place preference (Durand-de Cuttoli et al. 2018).

In addition to the $\beta 2$ subunit, lack of sustained nicotine self-administration has also been found in mice with knockout of the $\alpha 4$ and $\alpha 6$ nAChR subunits, and importantly, the behavioral phenotype could be restored with reexpression of these subunits in the VTA of each respective knockout line (Exley et al. 2011; Maskos et al. 2005; Picciotto et al. 1998; Pons et al. 2008). Further, dopaminergic neuron specific deletion of the $\alpha 4$ subunit was found to prevent the formation of a nicotine-mediated conditioned place preference (McGranahan et al. 2011). In a complementary approach, transgenic $\alpha 4$ and $\alpha 6$ nAChR hypersensitive knockin mice were generated, in which a single point mutation renders the receptor subtype more responsive to nicotine. For the $\alpha 4$ subunit, this genetic modification led to an enhancement of the rewarding effects of nicotine, as assessed with conditioned place preference (Tapper et al. 2004), and for the $\alpha 6$ subunit, mice exhibited a potentiation of nicotine-mediated locomotor effects and increased glutamatergic transmission with VTA neurons (Berry et al. 2015). As further evidence for these specific receptor subtypes, pharmacological administration of the relatively selective $\alpha 4\beta 2$ nAChR antagonist, DH β E, also decreased nicotine self-administration in rats (Corrigall and Coen 1989; Harvey et al. 1996; Watkins et al. 1999). These findings are paralleled by studies demonstrating that DH β E attenuates the stimulatory effects of nicotine on brain reward systems (Harrison et

al. 2002). Together, these findings support the notion that $\alpha 4\beta 2$ and/or $\alpha 4\alpha 6\beta 2$ nAChRs on dopaminergic circuits in the VTA mediate the reinforcing properties of nicotine.

The involvement of the $\alpha 7$ nAChR in nicotine dependence has been somewhat controversial. As noted above, glutamatergic axons containing presynaptic $\alpha 7$ nAChRs terminate on the soma of dopaminergic neurons in the VTA, suggesting a regulatory role for downstream dopaminergic signaling. Initial pharmacological studies demonstrated that administration of the $\alpha 7$ selective antagonist, methyllycaconitine, attenuates nicotine self-administration in rats (Markou and Paterson 2001), a finding that was further substantiated with site-specific VTA injections in wildtype mice (Besson et al. 2012). However, studies in $\alpha 7$ nAChR knockout mice failed to find differences with intravenous nicotine self-administration and nicotine-mediated conditioned place preference compared to wildtype littermates (Pons et al. 2008). However, more recently, Granon and colleagues (2012) were able to establish a dose-dependent effect with intra-VTA nicotine self-administration, in which the $\alpha 7$ nAChR knockout mice exhibited decreased self-administration at a low, but not high, nicotine dose. Further, when administered a peripheral injection of nicotine, nicotine-induced dopamine outflow in the NAc was sustained over a longer period of time in the $\alpha 7$ knockout mice (120 min), as compared to the wildtype mice (15 min) (Besson et al. 2012). In consideration of $\alpha 7$ nAChRs' presynaptic circuit localization, lower affinity for nicotine, and rapid recovery from desensitization, the receptor's effects on the mechanisms underlying nicotine reinforcement appear to be more nuanced.

Habenulo-Interpeduncular Pathway

As a drug of abuse, nicotine is distinctive in that the aversive properties appear to sharply contrast the rewarding properties of the drug, thereby limiting the range of doses that promote reinforcement and drug consumption. Nicotine's aversive effects are mediated by the medial habenula (MHb), a brain structure that directly projects to the interpeduncular nucleus (IPN). The MHb-IPN circuit has been characterized as containing the densest expression of cholinergic fibers and various nAChR subunits within the brain, including the $\alpha 5$, $\alpha 3$ and $\beta 4$ nAChR subunits (Marks et al. 1992; Villani et al. 1983). The aversive signaling of this circuit has been demonstrated in several studies with genetically modified rodents. For instance, $\alpha 5$ nAChR subunit knockout mice exhibit a high level of motivation to consume large quantities of nicotine, and viral mediated re-expression of $\alpha 5$ subunits within this pathway restores nicotine intake to wildtype levels (Fowler et al. 2011). In addition, while wildtype mice exhibit inhibitory motivational effects at high doses of nicotine, the $\alpha 5$ nAChR knockout mice continue to exhibit reward-related effects, as assessed with both conditioned place preference and intracranial self-stimulation (Fowler et al. 2013; Jackson et al. 2010). The conclusions drawn from the knockout mice are supported by complementary studies using viral mediated knockdown of the $\alpha 5$ nAChR subunit in rats, in which decreased expression of $\alpha 5$ nAChR subunits selectively in the habenula similarly increase nicotine intake and also decreased the inhibitory effects of higher nicotine doses on the activity of the brain reward circuitry (Fowler et al. 2011). Presynaptic $\alpha 5^*$ nAChRs on MHb terminals appear to facilitate glutamate release from cholinergic and glutamatergic coexpressing axons in the IPN (Fowler et al. 2011; Girod and Role 2001), which is thought to mediate this effect. Further, chronic nicotine appears to mitigate the activation

of a subpopulation of $\alpha 5$ -expressing neurons in the IPN, which subsequently provide negative feedback onto habenular terminals and mitigate nicotine reward, as assessed with conditioned place preference (Ables et al. 2017). The presence of the $\alpha 5$ nAChR subunit in $\alpha 4\beta 2$, $\alpha 3\beta 2$ and $\alpha 3\beta 4$ nAChR receptors have been shown to alter nicotine binding and/or desensitization kinetics *in vitro* (Ramirez-Latorre et al. 1996; Wang et al. 1996), and all of these subtypes are expressed in the MHb-IPN pathway. Furthermore, the $\beta 4$ nAChR subunit has also been shown to mediate aversive processing for nicotine. Under conditions of $\beta 4$ nAChR subunit over-expression, mice consume less nicotine solution (Frahm et al. 2011), thereby suggesting that an $\alpha 5\beta 4^*$ nAChR subtype may underlie an inhibitory motivational signal for nicotine in the MHb-IPN pathway. These findings in mouse models are further supported by human genome wide association studies demonstrating that allelic variation in the *CHRNA3-CHRNA5-CHRNA4* gene cluster, which encodes $\alpha 3$, $\alpha 5$ and $\beta 4$, respectively, increases vulnerability to developing tobacco dependence (Bierut et al. 2008; Kapoor et al. 2012; Wang et al. 2009). Recently, the non-synonymous SNP in the $\alpha 5$ gene that has been implicated in nicotine dependence in humans was inserted into the genome of rats to generate a transgenic humanized $\alpha 5$ SNP model (Forget et al. 2018). The behavior of the $\alpha 5$ SNP rat closely parallels the mouse knockout model, in which greater levels of nicotine are self-administered at high doses. In addition, an increase in nicotine-induced reinstatement was found in the $\alpha 5$ SNP rats (Forget et al. 2018), suggesting a role for this genetic variant in relapse-related behavior.

nAChRs in Other Aspects of Nicotine Dependence

Nicotine Enhancement of Cue Association

Nicotine administration has been shown to enhance the acquisition of certain learned behaviors, such as contextual fear conditioning and trace cued fear conditioning. These findings may underlie nicotine's cue-related conditioning effects with drug use, in that later exposure to the cue during abstinence may promote drug relapse. Nicotine's enhancing effect on contextual fear conditioning is prevented in mice with knockout of the $\beta 2$, but not $\alpha 7$, nAChR subunit (Davis and Gould 2007; Portugal et al. 2008). These effects likely involve the hippocampus since systemic or site-specific hippocampal administration of the $\beta 2$ nAChR antagonist DH β E mitigates contextual fear learning in wildtype, but not $\beta 2$ subunit knockout, mice (Davis and Gould 2007; Portugal et al. 2008). An enhancement of nicotine-mediated cued, but not trace or contextual, fear conditioning was also found in female, but not male, $\alpha 2$ nAChR subunit knockout mice (Lotfipour et al. 2013). Interestingly, mice with a hypersensitive $\alpha 2^*$ nAChR exhibit impaired contextual fear conditioning, an effect which could be rescued with pretreatment of nicotine (Lotfipour et al. 2017).

Nicotine Withdrawal

Following chronic nicotine administration, wildtype mice exhibit a range of behaviors indicative of the withdrawal state, including somatic signs (such as shaking, paw tremors, writhing), increased anxiety-like behavior in the elevated plus maze, increased brain reward thresholds, learning deficits in a contextual fear conditioning paradigm, and development of a conditioned place aversion to a withdrawal-associated environment. Studies with the $\beta 2$

knockout mouse indicate that $\beta 2^*$ nAChRs are involved in withdrawal-related anxiety-like behavior and conditioned place aversion, but not in the expression of somatic withdrawal signs (Jackson et al. 2008; Salas et al. 2004). Further, $\alpha 7$ nAChRs have been implicated in the initial expression of withdrawal symptomology, including anhedonia and somatic signs, but the $\alpha 7$ subunit knockout mice do not differ from wildtype mice at later time points (e.g., 24+ hours) (Grabus et al. 2005; Salas et al. 2007; Stoker et al. 2012). Moreover, decreased somatic withdrawal signs have been found in $\alpha 2$, $\alpha 5$ and $\beta 4$ nAChR subunit knockout mice, as compared to their respective wildtype littermates (Lotfipour et al. 2013; Salas et al. 2004; Salas et al. 2009). Interestingly, all of these subunits exhibit selectively dense expression in the MHb-IPN pathway, which has also been specifically implicated in somatic aspects of nicotine withdrawal. Administration of the general nAChR antagonist mecamylamine into the MHb-IPN pathway is sufficient to precipitate withdrawal, whereas injections into the cortex, VTA or hippocampus are ineffective (Salas et al. 2009), and re-exposure to nicotine during withdrawal results in increased activity of MHb and IPN neurons (Arvin et al. 2019; Gorlich et al. 2013). Further, injections of antagonists for $\alpha 4\beta 2^*$ or $\alpha 6\beta 2^*$, but not $\alpha 3\beta 4^*$, nAChRs in the MHb decrease the expression of anxiety-related behavior under conditions of nicotine withdrawal in mice (Pang et al. 2016). Together, these findings suggest that nAChRs are involved in various aspects of nicotine withdrawal based on their localization and expression patterns within the brain.

Modulators of nAChRs influencing expression and function

The expression and function of nAChRs may be modulated at various points from protein translation to membrane insertion to subsequent function. Early receptor binding studies in humans found increased expression of nAChRs in chronic smokers (Benwell et al. 1988; Perry et al. 1999), suggesting a change in cellular activation following prolonged nicotine exposure. Given that chronic agonist receptor activation typically results in receptor downregulation, this finding was unexpected, although it was also evidenced in more controlled rodent studies (Marks et al. 1983; Marks et al. 1992). The likely mechanism underlying receptor upregulation was recently elucidated as it was found that nicotine and nAChR ligands can act as ‘chaperones’ for $\alpha 4$ and $\beta 2$ nAChR subunits (Henderson et al. 2014; Kuryatov et al. 2005; Srinivasan et al. 2011), thereby allowing for increased expression of the high affinity nAChR subtype in the membrane. As the nAChR subunit protein is translated in the endoplasmic reticulum, the chaperone mechanism is thought to facilitate transport by promoting the trafficking of the protein to the plasma membrane, and subsequent insertion of the assembled nAChR.

Intracellular proteins have also been shown to stabilize nAChR subunits in the endoplasmic reticulum and regulate subunit assembly into specific nAChR subtypes, resulting in either an increase or decrease in nAChR subtype-specific membrane expression (Dau et al. 2013; Wanamaker and Green 2007). For instance, $\alpha 7$ nAChRs are selectively targeted to the dendritic membrane by Ric-3, thus facilitating receptor expression (Alexander et al. 2010). In contrast, members of the Ly-6/neurotoxin gene superfamily, which includes lynx1 and lynx2, have been demonstrated to decrease receptor expression by acting as inhibitory chaperones during protein translation and trafficking, and moreover, lynx proteins also bind directly to the extracellular face of nAChRs on the cell membrane, resulting in a

decrease in ligand binding efficiency and increase in the desensitization rate for nAChRs containing the $\alpha 4$, $\alpha 3$, $\alpha 5$, $\alpha 7$, $\beta 2$, and/or $\beta 4$ subunits (George et al. 2017; Ibanez-Tallon et al. 2002; Lyukmanova et al. 2011; Miwa et al. 1999; Nichols et al. 2014). In the cortex, Lynx1 is expressed in both glutamatergic and GABAergic neurons, whereas Lynx2 has been mainly localized in glutamatergic neurons (Demars and Morishita 2014). Lynx1 also appears to exhibit preferential binding affinity to the $\alpha : \alpha$ interface, which would allow for increased interaction with the stoichiometry present in the lower sensitivity $\alpha 4 \beta 2$ nAChRs (Nichols et al. 2014). In addition to intracellular proteins, other endogenous factors may interact with nAChRs to modulate function. For instance, estradiol has been shown to bind to the C-terminal tail of the $\alpha 4$ subunit to potentiate the activation of $\alpha 4^*$ nAChRs in the presence of acetylcholine, an effect that was selective for $\alpha 4$ as differences were not found with the $\alpha 3$ subunit (Curtis et al. 2002). More recently, phosphorylation sites have been identified on $\alpha 4 \beta 2^*$ nAChRs, suggesting a direct role for the receptor in mediating calcium/calmodulin-dependent protein kinase II and protein kinase A intracellular signaling (Miller et al. 2018). Together, these nAChR subtype specific interactions, along with cell type-specific expression patterns, may allow for selective modulation of various aspects of cholinergic signaling, thereby permitting each endogenous modulator to differentially regulate neural processes.

Beyond nicotine dependence

Although heavily involved in processes of nicotine dependence, nAChRs have also been implicated as mechanisms underlying other disease states, including Alzheimer's Disease (AD; (Lombardo and Maskos 2015)), schizophrenia (specifically, $\alpha 7$; (Jones 2018)), Parkinson's Disease (PD; (Jurado-Coronel et al. 2016)), overeating/weight gain (Shariff et al. 2016), among others. Discovery of these mechanisms has led to multiple Phase II clinical trials for nAChR compounds that have pro-cognitive effects (although many of these attempts have failed, see (Lewis et al. 2017)). Varenicline, a full agonist at $\alpha 7$ and a partial agonist at $\alpha 4 \beta 2$ nAChRs, is prescribed as a smoking cessation agent but also has efficacy in decreasing sucrose consumption and producing pro-cognitive effect in rodent models (Potasiewicz et al. 2018; Shariff et al. 2016). Interestingly, varenicline may improve cognitive function in patients with schizophrenia (Shim et al. 2012). In AD, medications have been developed that inhibit breakdown of the enzymes that metabolize acetylcholine (inhibition of acetylcholinesterase and/or butyrylcholinesterase), such as Donepezil (Aricept) or Rivastigmine (Exelon). Additionally, drug development efforts have included compounds that act as positive allosteric modulators at $\alpha 7$ nAChRs in addition to AChE inhibition, including Galantamine (Reminyl). Galantamine slows progression of plaque formation preclinically (Bhattacharya et al. 2014), and has shown efficacy in improving cognition and global functioning in patients with AD (Deardorff et al. 2015). Although statistically significant, these benefits are modest and thus additional drugs are needed. Taken together, these studies illustrate a need for refinement of medications that target nAChRs for indications beyond nicotine dependence.

Conclusions

Since the mid-1990's, significant advances have been made with transgenic animal models to allow for better interrogation of specific nAChRs and circuits underlying nicotine dependence. Studies have built upon prior findings to reveal integral roles for various subunits in the mechanisms underlying nicotine's actions in the brain, with relevance to addiction. The $\alpha 4\alpha 6\beta 2^*$ nAChRs in the mesolimbic pathway appear to be important in mediating the reinforcing properties of nicotine, whereas the $\alpha 5$ and $\beta 4$ nAChR subunits in the MHb-IPN mitigate the aversive properties of higher nicotine doses that thereby limit drug intake. In addition to these effects on drug consumption, nAChRs have also been implicated in other aspects of the dependence processes, including withdrawal, cue-associated learning, and psychiatric comorbidity. This foundation holds the promise to provide the field with a basis for new discoveries to formulate more efficacious therapeutics. For instance, in consideration of the involvement of the $\alpha 4\beta 2^*$ nAChRs in nicotine reinforcement, it is perhaps not surprising that varenicline has similar or greater effectiveness in promoting smoking cessation compared to nicotine replacement therapy and other approved therapeutics, such as bupropion (Gonzales et al. 2006). Drug development efforts are also focused on modulating the MHb-IPN circuit to enhance nicotine-mediated aversion and thus decrease further drug intake (Fowler and Kenny 2014; Jin et al. 2014). For instance, GLP-1 receptors have been shown to alter nicotine intake via modulation of the MHb-IPN circuit (Tuesta et al. 2017), and a GLP-1 receptor agonist, liraglutide, is currently being tested for smoking cessation in a clinical trial (Ashare 2019). In another approach to minimize nicotine entry into the brain, NicA2-J1 has been developed as a reengineered nicotine-degrading enzyme (Kallupi et al. 2018). Interestingly, while NicA2-J1 does not appear to induce significant differences in nicotine intake, decreased withdrawal and relapse-related behaviors were found in rats (Kallupi et al. 2018). Therefore, the field will certainly continue to advance by better defining the various genetic, behavioral and biological mechanisms underlying addiction so that long-term abstinence can be readily achieved by those seeking to quit tobacco and e-cigarettes.

REFERENCES

- Ables JLet al. (2017) Retrograde inhibition by a specific subset of interpeduncular alpha5 nicotinic neurons regulates nicotine preference Proceedings of the National Academy of Sciences of the United States of America 114:13012–13017. doi:10.1073/pnas.1717506114 [PubMed: 29158387]
- Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function Physiol Rev 89:73–120. doi:10.1152/physrev.00015.2008 [PubMed: 19126755]
- Alexander JK, Sagher D, Krivoshein AV, Criado M, Jefford G, Green WN (2010) Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites The Journal of neuroscience : the official journal of the Society for Neuroscience 30:10112–10126. doi:10.1523/JNEUROSCI.6344-09.2010 [PubMed: 20668195]
- Arvin MCet al. (2019) Chronic nicotine exposure alters the neurophysiology of habenulo-interpeduncular circuitry The Journal of neuroscience : the official journal of the Society for Neuroscience, in press. doi:10.1523/JNEUROSCI.2816-18.2019
- Ashare R (2019) Daily Liraglutide for Nicotine Dependence, NCT03712098. <https://ClinicalTrials.gov/show/NCT03712098>.
- Bellavia A, Wolk A, Orsini N (2016) Differences in age at death according to smoking and age at menopause Menopause 23:108–110. doi:10.1097/GME.0000000000000501 [PubMed: 26240946]

- Benwell ME, Balfour DJ, Anderson JM (1988) Evidence that tobacco smoking increases the density of (–)-[3H]nicotine binding sites in human brain *Journal of neurochemistry* 50:1243–1247 [PubMed: 3346676]
- Berry JN, Engle SE, McIntosh JM, Drenan RM (2015) $\alpha 6$ -Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity *Neuroscience* 304:161–175. doi:10.1016/j.neuroscience.2015.07.052 [PubMed: 26210579]
- Besson ME et al. (2012) $\alpha 7$ -nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice *Psychopharmacology* 220:1–14. doi:10.1007/s00213-011-2422-1 [PubMed: 21901321]
- Bhattacharya S, Haertel C, Maelicke A, Montag D (2014) Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease *PloS one* 9:e89454. doi:10.1371/journal.pone.0089454 [PubMed: 24586789]
- Bierut LJ et al. (2008) Variants in nicotinic receptors and risk for nicotine dependence *The American journal of psychiatry* 165:1163–1171 [PubMed: 18519524]
- Bohler S, Gay S, Bertrand S, Corringer PJ, Edelstein SJ, Changeux JP, Bertrand D (2001) Desensitization of neuronal nicotinic acetylcholine receptors conferred by N-terminal segments of the $\beta 2$ subunit *Biochemistry* 40:2066–2074 [PubMed: 11329274]
- Boulter J, Connolly J, Deneris E, Goldman D, Heinemann S, Patrick J (1987) Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family *Proceedings of the National Academy of Sciences of the United States of America* 84:7763–7767 [PubMed: 2444984]
- Brody AL et al. (2006) Cigarette smoking saturates brain $\alpha 4 \beta 2$ nicotinic acetylcholine receptors *Archives of general psychiatry* 63:907–915. doi:10.1001/archpsyc.63.8.907 [PubMed: 16894067]
- Broide RS, Leslie FM (1999) The $\alpha 7$ nicotinic acetylcholine receptor in neuronal plasticity *Mol Neurobiol* 20:1–16. doi:10.1007/BF02741361 [PubMed: 10595869]
- Changeux JP et al. (1998) Brain nicotinic receptors: structure and regulation, role in learning and reinforcement *Brain research Brain research reviews* 26:198–216 [PubMed: 9651527]
- Charpentier E, Barneoud P, Moser P, Besnard F, Sgard F (1998) Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area *Neuroreport* 9:3097–3101 [PubMed: 9804323]
- Chen X et al. (2009) Variants in nicotinic acetylcholine receptors $\alpha 5$ and $\alpha 3$ increase risks to nicotine dependence *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 150B:926–933. doi:10.1002/ajmg.b.30919
- Chini B, Clementi F, Hukovic N, Sher E (1992) Neuronal-type α -bungarotoxin receptors and the $\alpha 5$ -nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines *Proceedings of the National Academy of Sciences of the United States of America* 89:1572–1576. doi:10.1073/pnas.89.5.1572 [PubMed: 1542648]
- Christensen MH, Kohlmeier KA (2016) Age-related changes in functional postsynaptic nicotinic acetylcholine receptor subunits in neurons of the laterodorsal tegmental nucleus, a nucleus important in drug addiction *Addict Biol* 21:267–281. doi:10.1111/adb.12194 [PubMed: 25363563]
- Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A (1985) Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]- α -bungarotoxin *The Journal of neuroscience : the official journal of the Society for Neuroscience* 5:1307–1315 [PubMed: 3998824]
- Colombo SF, Mazzeo F, Pistillo F, Gotti C (2013) Biogenesis, trafficking and up-regulation of nicotinic ACh receptors *Biochem Pharmacol* 86:1063–1073. doi:10.1016/j.bcp.2013.06.023 [PubMed: 23830821]
- Corrigall WA, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule *Psychopharmacology* 99:473–478 [PubMed: 2594913]

- Couturier Set al. (1990) A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX *Neuron* 5:847–856 [PubMed: 1702646]
- Curtis L, Buisson B, Bertrand S, Bertrand D (2002) Potentiation of human alpha4beta2 neuronal nicotinic acetylcholine receptor by estradiol *Molecular pharmacology* 61:127–135 [PubMed: 11752213]
- Dau A, Komal P, Truong M, Morris G, Evans G, Nashmi R (2013) RIC-3 differentially modulates alpha4beta2 and alpha7 nicotinic receptor assembly, expression, and nicotine-induced receptor upregulation *BMC neuroscience* 14:47. doi:10.1186/1471-2202-14-47 [PubMed: 23586521]
- Davis JA, Gould TJ (2007) beta2 subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice *Psychopharmacology* 190:343–352. doi:10.1007/s00213-006-0624-8 [PubMed: 17136517]
- Deardorff WJ, Feen E, Grossberg GT (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease *Drugs & aging* 32:537–547. doi:10.1007/s40266-015-0273-x [PubMed: 26033268]
- Demars MP, Morishita H (2014) Cortical parvalbumin and somatostatin GABA neurons express distinct endogenous modulators of nicotinic acetylcholine receptors *Mol Brain* 7:75. doi:10.1186/s13041-014-0075-9 [PubMed: 25359633]
- Drisdell RC, Green WN (2000) Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers *The Journal of neuroscience : the official journal of the Society for Neuroscience* 20:133–139 [PubMed: 10627589]
- Durand-de Cuttoli Ret al. (2018) Manipulating midbrain dopamine neurons and reward-related behaviors with light-controllable nicotinic acetylcholine receptors *Elife* 7. doi:10.7554/eLife.37487
- Exley Ret al. (2011) Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine *Proceedings of the National Academy of Sciences of the United States of America* 108:7577–7582. doi:10.1073/pnas.1103000108 [PubMed: 21502501]
- Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001) Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus *The Journal of neuroscience : the official journal of the Society for Neuroscience* 21:7993–8003 [PubMed: 11588172]
- Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, Lester RA (1999a) Desensitization of nicotinic receptors in the central nervous system *Annals of the New York Academy of Sciences* 868:620–623 [PubMed: 10414343]
- Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA (1997) Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine *The Journal of neuroscience : the official journal of the Society for Neuroscience* 17:5747–5759 [PubMed: 9221773]
- Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA (1999b) Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine *The Journal of neuroscience : the official journal of the Society for Neuroscience* 19:4804–4814 [PubMed: 10366615]
- Forget Bet al. (2018) A Human Polymorphism in CHRNA5 Is Linked to Relapse to Nicotine Seeking in Transgenic Rats *Current biology : CB* 28:3244–3253 e3247. doi:10.1016/j.cub.2018.08.044 [PubMed: 30293722]
- Fowler CD et al. (2017) Basic Science and Public Policy: Informed Regulation for Nicotine and Tobacco Products *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. doi:10.1093/ntr/ntx175
- Fowler CD, Kenny PJ (2014) Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability *Neuropharmacology* 76 Pt B:533–544. doi:10.1016/j.neuropharm.2013.09.008 [PubMed: 24055497]
- Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011) Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake *Nature* 471:597–601 [PubMed: 21278726]

- Fowler CD, Tuesta L, Kenny PJ (2013) Role of alpha5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice *Psychopharmacology*:in press
- Frahm Set al. (2011) Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula *Neuron* 70:522–535. doi:10.1016/j.neuron.2011.04.013 [PubMed: 21555077]
- Gaimarri A, Moretti M, Riganti L, Zanardi A, Clementi F, Gotti C (2007) Regulation of neuronal nicotinic receptor traffic and expression *Brain research reviews* 55:134–143. doi:10.1016/j.brainresrev.2007.02.005 [PubMed: 17383007]
- Gao Fet al. (2005) Agonist-mediated conformational changes in acetylcholine-binding protein revealed by simulation and intrinsic tryptophan fluorescence *J Biol Chem* 280:8443–8451. doi:10.1074/jbc.M412389200 [PubMed: 15591050]
- Gentry CL, Lukas RJ (2002) Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure *Curr Drug Targets CNS Neurol Disord* 1:359–385 [PubMed: 12769610]
- George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P (2017) Isoform-specific mechanisms of alpha3beta4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1 *FASEB J* 31:1398–1420. doi:10.1096/fj.201600733R [PubMed: 28100642]
- George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X, Whiteaker P (2012) Function of human alpha3beta4alpha5 nicotinic acetylcholine receptors is reduced by the alpha5(D398N) variant *J Biol Chem* 287:25151–25162. doi:10.1074/jbc.M112.379339 [PubMed: 22665477]
- Giniatullin R, Nistri A, Yakel JL (2005) Desensitization of nicotinic ACh receptors: shaping cholinergic signaling *Trends in neurosciences* 28:371–378. doi:10.1016/j.tins.2005.04.009 [PubMed: 15979501]
- Ginzkey C, Friehs G, Koehler C, Hackenberg S, Hagen R, Kleinsasser NH (2013) Assessment of nicotine-induced DNA damage in a genotoxicological test battery *Mutat Res* 751:34–39. doi:10.1016/j.mrgentox.2012.11.004 [PubMed: 23200805]
- Ginzkey Cet al. (2012) Analysis of nicotine-induced DNA damage in cells of the human respiratory tract *Toxicology letters* 208:23–29. doi:10.1016/j.toxlet.2011.09.029 [PubMed: 22001448]
- Girod R, Role LW (2001) Long-lasting enhancement of glutamatergic synaptic transmission by acetylcholine contrasts with response adaptation after exposure to low-level nicotine *The Journal of neuroscience : the official journal of the Society for Neuroscience* 21:5182–5190. doi:10.1523/JNEUROSCI.1143-01.2001 [PubMed: 11438593]
- Gonzales Det al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial *JAMA : the journal of the American Medical Association* 296:47–55 [PubMed: 16820546]
- Gorlich A, Antolin-Fontes B, Ables JL, Frahm S, Slimak MA, Dougherty JD, Ibanez-Tallon I (2013) Reexposure to nicotine during withdrawal increases the pacemaking activity of cholinergic habenular neurons *Proceedings of the National Academy of Sciences of the United States of America* 110:17077–17082 [PubMed: 24082085]
- Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance *Trends Pharmacol Sci* 27:482–491. doi:S0165-6147(06)00175-1 [pii] 10.1016/j.tips.2006.07.004 [PubMed: 16876883]
- Grabus SD, Martin BR, Imad Damaj M (2005) Nicotine physical dependence in the mouse: involvement of the alpha7 nicotinic receptor subtype *European journal of pharmacology* 515:90–93 [PubMed: 15896732]
- Graham AJ et al. (2003) Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus *J Chem Neuroanat* 25:97–113 [PubMed: 12663058]
- Hajek Pet al. (2019) A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy *N Engl J Med* 380:629–637. doi:10.1056/NEJMoa1808779 [PubMed: 30699054]
- Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y (2005) Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations *EMBO J* 24:3635–3646. doi:10.1038/sj.emboj.7600828 [PubMed: 16193063]

- Harrison AA, Gasparini F, Markou A (2002) Nicotine potentiation of brain stimulation reward reversed by DHbE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats *Psychopharmacology* 160:56–66 [PubMed: 11862374]
- Harvey SC, Maddox FN, Luetje CW (1996) Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits *Journal of neurochemistry* 67:1953–1959 [PubMed: 8863500]
- Hawkins BT, Abbruscato TJ, Eggleton RD, Brown RC, Huber JD, Campos CR, Davis TP (2004) Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution *Brain research* 1027:48–58. doi:10.1016/j.brainres.2004.08.043 [PubMed: 15494156]
- Henderson BJ et al. (2014) Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors *J Gen Physiol* 143:51–66. doi:10.1085/jgp.201311102 [PubMed: 24378908]
- Hendrickson LM, Guildford MJ, Tapper AR (2013) Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence *Frontiers in psychiatry* 4:29. doi:10.3389/fpsy.2013.00029 [PubMed: 23641218]
- Ibanez-Tallon I, Miwa JM, Wang HL, Adams NC, Crabtree GW, Sine SM, Heintz N (2002) Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1 *Neuron* 33:893–903. doi:S0896627302006323 [pii] [PubMed: 11906696]
- Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, Damaj MI (2010) Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice *The Journal of pharmacology and experimental therapeutics* 334:137–146 [PubMed: 20400469]
- Jackson KJ, Martin BR, Changeux JP, Damaj MI (2008) Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs *The Journal of pharmacology and experimental therapeutics* 325:302–312 [PubMed: 18184829]
- Jacob T, Clouden N, Hingorani A, Ascher E (2009) The effect of cotinine on telomerase activity in human vascular smooth muscle cells *J Cardiovasc Surg (Torino)* 50:345–349
- Jain A, Kuryatov A, Wang J, Kamenecka TM, Lindstrom J (2016) Unorthodox Acetylcholine Binding Sites Formed by alpha5 and beta3 Accessory Subunits in alpha4beta2* Nicotinic Acetylcholine Receptors *J Biol Chem* 291:23452–23463. doi:10.1074/jbc.M116.749150 [PubMed: 27645992]
- Jensen JJ, Winzer-Serhan UH, Leslie FM (1997) Glial regulation of alpha 7-type nicotinic acetylcholine receptor expression in cultured rat cortical neurons *Journal of neurochemistry* 68:112–120 [PubMed: 8978716]
- Jia Yet al. (2016) Nicotine Inhibits Cisplatin-Induced Apoptosis via Regulating alpha5-nAChR/AKT Signaling in Human Gastric Cancer Cells *PloS one* 11:e0149120. doi:10.1371/journal.pone.0149120
- Jin X, Bermudez I, Steinbach JH (2014) The nicotinic alpha5 subunit can replace either an acetylcholine-binding or nonbinding subunit in the alpha4beta2* neuronal nicotinic receptor *Molecular pharmacology* 85:11–17. doi:10.1124/mol.113.089979 [PubMed: 24184962]
- Jones C (2018) alpha7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia *Journal of clinical psychopharmacology* 38:247–249. doi:10.1097/JCP.0000000000000859 [PubMed: 29505470]
- Jurado-Coronel JC, Avila-Rodriguez M, Capani F, Gonzalez J, Moran VE, Barreto GE (2016) Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential Therapeutic Target in Parkinson's Disease *Current pharmaceutical design* 22:1305–1311 [PubMed: 26972289]
- Kaiser S, Wonnacott S (2000) alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release *Molecular pharmacology* 58:312–318 [PubMed: 10908298]
- Kallupi M, Xue S, Zhou B, Janda KD, George O (2018) An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse *Sci Adv* 4:eaat4751. doi:10.1126/sciadv.aat4751

- Kaneda K (2017) The contribution of neuroplasticity induced in cholinergic neurons of the laterodorsal tegmental nucleus to cocaine addiction *Nihon shinkei seishin yakurigaku zasshi* = Japanese journal of psychopharmacology 37:1–7 [PubMed: 30452815]
- Kaneda K, Kamii H, Taoka N, Minami M (2016) The role of neuroplasticity in cholinergic neurons of the laterodorsal tegmental nucleus for cocaine addiction *Nihon Arukoru Yakubutsu Igakkai zasshi* = Japanese journal of alcohol studies & drug dependence 51:259–267 [PubMed: 30478016]
- Kapoor Met al. (2012) Variants located upstream of CHRNA4 on chromosome 15q25.1 are associated with age at onset of daily smoking and habitual smoking *PLoS one* 7:e33513 [PubMed: 22438940]
- Karlin A (2002) Emerging structure of the nicotinic acetylcholine receptors *Nat Rev Neurosci* 3:102–114 [PubMed: 11836518]
- Kenny PJ, Markou A (2005) Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems *The Journal of neuroscience : the official journal of the Society for Neuroscience* 25:6208–6212. doi:25/26/6208 [pii] 10.1523/JNEUROSCI.4785-04.2005 [PubMed: 15987950]
- Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei *The Journal of neuroscience : the official journal of the Society for Neuroscience* 21:1452–1463 [PubMed: 11222635]
- Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human $\alpha 4\beta 2$ acetylcholine receptors *Molecular pharmacology* 68:1839–1851. doi:10.1124/mol.105.012419 [PubMed: 16183856]
- Lallai Vet al. (2019) Nicotine Acts on Cholinergic Signaling Mechanisms to Directly Modulate Choroid Plexus Function *eNeuro* 6. doi:10.1523/ENEURO.0051-19.2019
- Lee HW et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells *Proceedings of the National Academy of Sciences of the United States of America* 115:E1560–E1569. doi:10.1073/pnas.1718185115 [PubMed: 29378943]
- Lewis AS, van Schalkwyk GI, Bloch MH (2017) Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies *Progress in neuro-psychopharmacology & biological psychiatry* 75:45–53. doi:10.1016/j.pnpbp.2017.01.001 [PubMed: 28065843]
- Lombardo S, Maskos U (2015) Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment *Neuropharmacology* 96:255–262. doi:10.1016/j.neuropharm.2014.11.018 [PubMed: 25514383]
- Lotfipour Set al. (2013) Targeted deletion of the mouse $\alpha 2$ nicotinic acetylcholine receptor subunit gene (*Chrna2*) potentiates nicotine-modulated behaviors *The Journal of neuroscience : the official journal of the Society for Neuroscience* 33:7728–7741 [PubMed: 23637165]
- Lotfipour Set al. (2017) $\alpha 2^*$ Nicotinic acetylcholine receptors influence hippocampus-dependent learning and memory in adolescent mice *Learning & memory* 24:231–244. doi:10.1101/lm.045369.117 [PubMed: 28507032]
- Lyukmanova EN et al. (2011) NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human LYNX1 *J Biol Chem* 286:10618–10627. doi:10.1074/jbc.M110.189100 [PubMed: 21252236]
- Ma X et al. (2014) $\alpha 5$ Nicotinic acetylcholine receptor mediates nicotine-induced HIF-1 α and VEGF expression in non-small cell lung cancer *Toxicology and applied pharmacology* 278:172–179. doi:10.1016/j.taap.2014.04.023 [PubMed: 24793809]
- Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP, Faure P (2006) Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors *Neuron* 50:911–921 [PubMed: 16772172]
- Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas *Neuron* 33:905–919 [PubMed: 11906697]
- Mansvelder HD, McGehee DS (2002) Cellular and synaptic mechanisms of nicotine addiction *J Neurobiol* 53:606–617. doi:10.1002/neu.10148 [PubMed: 12436424]

- Markou A, Paterson NE (2001) The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 3:361–373 [PubMed: 11694204]
- Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors *The Journal of pharmacology and experimental therapeutics* 226:817–825 [PubMed: 6887012]
- Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment *The Journal of neuroscience : the official journal of the Society for Neuroscience* 12:2765–2784 [PubMed: 1613557]
- Maskos U et al. (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors *Nature* 436:103–107. doi:nature03694 [pii] 10.1038/nature03694 [PubMed: 16001069]
- McGehee DS, Heath MJ, Gelber S, Devay P, Role LW (1995) Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors *Science* 269:1692–1696 [PubMed: 7569895]
- McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK (2011) Alpha4beta2 Nicotinic Acetylcholine Receptors on Dopaminergic Neurons Mediate Nicotine Reward and Anxiety Relief *The Journal of neuroscience : the official journal of the Society for Neuroscience* 31:10891–10902. doi:10.1523/JNEUROSCI.0937-11.2011 [pii] 10.1523/JNEUROSCI.0937-11.2011 [PubMed: 21795541]
- Miech R, Johnston L, O'Malley PM, Bachman JG, Patrick ME (2019) Adolescent Vaping and Nicotine Use in 2017–2018 - U.S. National Estimates *N Engl J Med* 380:192–193. doi:10.1056/NEJMc1814130 [PubMed: 30554549]
- Mifsud JC, Hernandez L, Hoebel BG (1989) Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis *Brain research* 478:365–367 [PubMed: 2924134]
- Miller MB, Wilson RS, Lam TT, Nairn AC, Picciotto MR (2018) Evaluation of the Phosphoproteome of Mouse Alpha 4/Beta 2-Containing Nicotinic Acetylcholine Receptors In Vitro and In Vivo *Proteomes* 6. doi:10.3390/proteomes6040042
- Miller PS, Smart TG (2010) Binding, activation and modulation of Cys-loop receptors *Trends Pharmacol Sci* 31:161–174. doi:10.1016/j.tips.2009.12.005 [PubMed: 20096941]
- Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, Heintz N (1999) Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS *Neuron* 23:105–114 [PubMed: 10402197]
- Mucchiello V, Crespi A, Fasoli F, Clementi F, Gotti C (2016) Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment *Current pharmaceutical design* 22:2160–2169 [PubMed: 26845123]
- Nakada Tet al. (2012) Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway *J Toxicol Sci* 37:555–563 [PubMed: 22687995]
- Nichols WA, Henderson BJ, Yu C, Parker RL, Richards CI, Lester HA, Miwa JM (2014) Lynx1 shifts alpha4beta2 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum *J Biol Chem* 289:31423–31432. doi:10.1074/jbc.M114.573667 [PubMed: 25193667]
- Nisell M, Nomikos GG, Svensson TH (1994) Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area *Synapse* 16:36–44. doi:10.1002/syn.890160105 [PubMed: 8134899]
- Noda M, Kobayashi AI (2017) Nicotine inhibits activation of microglial proton currents via interactions with alpha7 acetylcholine receptors *J Physiol Sci* 67:235–245. doi:10.1007/s12576-016-0460-5 [PubMed: 27256075]
- Orejarena MJ, Herrera-Solis A, Pons S, Maskos U, Maldonado R, Robledo P (2012) Selective re-expression of beta2 nicotinic acetylcholine receptor subunits in the ventral tegmental area of the mouse restores intravenous nicotine self-administration *Neuropharmacology* 63:235–241. doi:10.1016/j.neuropharm.2012.03.011 [PubMed: 22480616]

- Pang X, Liu L, Ngolab J, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR (2016) Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors *Neuropharmacology* 107:294–304. doi:10.1016/j.neuropharm.2016.03.039 [PubMed: 27020042]
- Papke RL, Porter Papke JK (2002) Comparative pharmacology of rat and human $\alpha 7$ nAChR conducted with net charge analysis *British journal of pharmacology* 137:49–61. doi:10.1038/sj.bjp.0704833 [PubMed: 12183330]
- Paradiso KG, Steinbach JH (2003) Nicotine is highly effective at producing desensitization of rat $\alpha 4\beta 2$ neuronal nicotinic receptors *The Journal of physiology* 553:857–871. doi:10.1113/jphysiol.2003.053447 [PubMed: 14555718]
- Patrick J, Stallcup B (1977) α -Bungarotoxin binding and cholinergic receptor function on a rat sympathetic nerve line *J Biol Chem* 252:8629–8633 [PubMed: 925016]
- Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies *The Journal of pharmacology and experimental therapeutics* 289:1545–1552 [PubMed: 10336551]
- Piccio MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not “either/or”: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood *Prog Neurobiol* 84:329–342. doi:10.1016/j.pneurobio.2007.12.005 [PubMed: 18242816]
- Piccio MR et al. (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain *Nature* 374:65–67. doi:10.1038/374065a0 [PubMed: 7870173]
- Piccio MR et al. (1998) Acetylcholine receptors containing the $\beta 2$ subunit are involved in the reinforcing properties of nicotine *Nature* 391:173–177. doi:10.1038/34413 [PubMed: 9428762]
- Pons S et al. (2008) Crucial role of $\alpha 4$ and $\alpha 6$ nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration *The Journal of neuroscience : the official journal of the Society for Neuroscience* 28:12318–12327. doi:10.1523/JNEUROSCI.3918-08.2008 [PubMed: 19020025]
- Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs *Nature* 382:255–257 [PubMed: 8717040]
- Portugal GS, Kenney JW, Gould TJ (2008) $\beta 2$ subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning *Neurobiology of learning and memory* 89:106–113. doi:10.1016/j.nlm.2007.05.002 [PubMed: 17584502]
- Potasiewicz A, Golebiowska J, Popik P, Nikiforuk A (2018) Procognitive effects of varenicline in the animal model of schizophrenia depend on $\alpha 4\beta 2$ - and $\alpha 7$ -nicotinic acetylcholine receptors *Journal of psychopharmacology* 269881118812097. doi:10.1177/0269881118812097
- Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors *J Neurobiol* 53:457–478. doi:10.1002/neu.10109 [PubMed: 12436413]
- Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L (1996) Functional contributions of $\alpha 5$ subunit to neuronal acetylcholine receptor channels *Nature* 380:347–351 [PubMed: 8598930]
- Rennie LJ, Bazillier-Bruneau C, Rouesse J (2016) Harm Reduction or Harm Introduction? Prevalence and Correlates of E-Cigarette Use Among French Adolescents *J Adolesc Health* 58:440–445. doi:10.1016/j.jadohealth.2015.12.013 [PubMed: 26852249]
- Reuben M, Boye S, Clarke PB (2000) Nicotinic receptors modulating somatodendritic and terminal dopamine release differ pharmacologically *European journal of pharmacology* 393:39–49 [PubMed: 10770996]
- Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum *Nat Neurosci* 7:583–584 [PubMed: 15146188]
- Saccone NL et al. (2009) Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 150B:453–466

- Saccone SF et al. (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs *Human molecular genetics* 16:36–49 [PubMed: 17135278]
- Salas R, Main A, Gangitano D, De Biasi M (2007) Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit *Neuropharmacology* 53:863–869 [PubMed: 17920082]
- Salas R, Pieri F, De Biasi M (2004) Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit *The Journal of neuroscience : the official journal of the Society for Neuroscience* 24:10035–10039 [PubMed: 15537871]
- Salas R, Sturm R, Boulter J, De Biasi M (2009) Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice *The Journal of neuroscience : the official journal of the Society for Neuroscience* 29:3014–3018 [PubMed: 19279237]
- Selya AS, Dierker L, Rose JS, Hedeker D, Mermelstein RJ (2018) The Role of Nicotine Dependence in E-Cigarettes' Potential for Smoking Reduction *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 20:1272–1277. doi:10.1093/ntr/ntx160 [PubMed: 29065204]
- Shariff Met al. (2016) Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake *PloS one* 11:e0150270. doi:10.1371/journal.pone.0150270
- Shen JX, Yakel JL (2012) Functional alpha7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices *J Mol Neurosci* 48:14–21. doi:10.1007/s12031-012-9719-3 [PubMed: 22351110]
- Shim JC et al. (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 37:660–668. doi:10.1038/npp.2011.238 [PubMed: 22048460]
- Shinohara F, Kihara Y, Ide S, Minami M, Kaneda K (2014) Critical role of cholinergic transmission from the laterodorsal tegmental nucleus to the ventral tegmental area in cocaine-induced place preference *Neuropharmacology* 79:573–579. doi:10.1016/j.neuropharm.2014.01.019 [PubMed: 24467849]
- Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux JP (2002) The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion *Neuropharmacology* 42:530–539 [PubMed: 11955523]
- Shytle RD et al. (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors *Journal of neurochemistry* 89:337–343. doi:10.1046/j.1471-4159.2004.02347.x [PubMed: 15056277]
- Sifat AE, Vaidya B, Kaisar MA, Cucullo L, Abbruscato TJ (2018) Nicotine and electronic cigarette (E-Cig) exposure decreases brain glucose utilization in ischemic stroke *Journal of neurochemistry* 147:204–221. doi:10.1111/jnc.14561 [PubMed: 30062776]
- Sine SM et al. (2002) Naturally occurring mutations at the acetylcholine receptor binding site independently alter ACh binding and channel gating *J Gen Physiol* 120:483–496. doi:10.1085/jgp.20028568 [PubMed: 12356851]
- Sottile SY, Ling L, Cox BC, Caspary DM (2017) Impact of ageing on postsynaptic neuronal nicotinic neurotransmission in auditory thalamus *The Journal of physiology* 595:5375–5385. doi:10.1113/JP274467 [PubMed: 28585699]
- Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, Lester HA (2011) Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning *J Gen Physiol* 137:59–79. doi:10.1085/jgp.201010532 [PubMed: 21187334]
- St Helen G, Havel C, Dempsey DA, Jacob P 3rd, Benowitz NL (2016) Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes *Addiction* 111:535–544. doi:10.1111/add.13183 [PubMed: 26430813]
- Stoker AK, Olivier B, Markou A (2012) Role of alpha7- and beta4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice *Behavior genetics* 42:423–436 [PubMed: 22009521]
- Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive *Psychopharmacology* 117:2–10 discussion 14–20 [PubMed: 7724697]

- Strasser AA, Souprountchouk V, Kaufmann A, Blazekovic S, Leone F, Benowitz NL, Schnoll RA (2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes Tobacco regulatory science 2:352–362. doi:10.18001/TRS.2.4.7 [PubMed: 27942543]
- Sun H, Ma X (2015) alpha5-nAChR modulates nicotine-induced cell migration and invasion in A549 lung cancer cells Exp Toxicol Pathol 67:477–482. doi:10.1016/j.etp.2015.07.001 [PubMed: 26205096]
- Taoka N, Kamiizawa R, Wada S, Minami M, Kaneda K (2016) Chronic cocaine exposure induces noradrenergic modulation of inhibitory synaptic transmission to cholinergic neurons of the laterodorsal tegmental nucleus The European journal of neuroscience 44:3035–3045. doi:10.1111/ejn.13405 [PubMed: 27646204]
- Tapper ARet al. (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization Science 306:1029–1032. doi:306/5698/1029 [pii] 10.1126/science.1099420 [PubMed: 15528443]
- Tuesta LMet al. (2017) GLP-1 acts on habenular avoidance circuits to control nicotine intake Nat Neurosci 20:708–716. doi:10.1038/nn.4540 [PubMed: 28368384]
- Villani L, Contestabile A, Niso R (1983) Ultrastructural features and acetylcholinesterase histochemistry of the rat habenular complex Acta Anat (Basel) 117:112–120 [PubMed: 6637374]
- Walters CL, Brown S, Changeux JP, Martin B, Damaj MI (2006) The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice Psychopharmacology 184:339–344. doi:10.1007/s00213-005-0295-x [PubMed: 16416156]
- Wanamaker CP, Green WN (2007) Endoplasmic reticulum chaperones stabilize nicotinic receptor subunits and regulate receptor assembly J Biol Chem 282:31113–31123. doi:10.1074/jbc.M705369200 [PubMed: 17728248]
- Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J (1996) Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits J Biol Chem 271:17656–17665 [PubMed: 8663494]
- Wang JCet al. (2009) Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence Molecular psychiatry 14:501–510 [PubMed: 18414406]
- Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A (2018) Tobacco Product Use Among Middle and High School Students - United States, 2011–2017 MMWR Morbidity and mortality weekly report 67:629–633. doi:10.15585/mmwr.mm6722a3 [PubMed: 29879097]
- Wang X, Lippi G, Carlson DM, Berg DK (2013) Activation of alpha7-containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses Journal of neurochemistry 127:632–643. doi:10.1111/jnc.12436 [PubMed: 24032433]
- Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats Pharmacology, biochemistry, and behavior 62:743–751
- Wonnacott S (1997) Presynaptic nicotinic ACh receptors Trends in neurosciences 20:92–98 [PubMed: 9023878]
- Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters J Mol Neurosci 30:137–140. doi:10.1385/JMN:30:1:137 [PubMed: 17192660]
- Yan Yet al. (2018) Nicotinic Cholinergic Receptors in VTA Glutamate Neurons Modulate Excitatory Transmission Cell reports 23:2236–2244. doi:10.1016/j.celrep.2018.04.062 [PubMed: 29791835]
- Yoshikawa H, Hellstrom-Lindahl E, Grill V (2005) Evidence for functional nicotinic receptors on pancreatic beta cells Metabolism: clinical and experimental 54:247–254. doi:10.1016/j.metabol.2004.08.020 [PubMed: 15690320]
- Zia S, Ndoeye A, Nguyen VT, Grando SA (1997) Nicotine enhances expression of the alpha 3, alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells Research communications in molecular pathology and pharmacology 97:243–262 [PubMed: 9387186]
- Zoli M, Pistillo F, Gotti C (2015) Diversity of native nicotinic receptor subtypes in mammalian brain Neuropharmacology 96:302–311. doi:10.1016/j.neuropharm.2014.11.003 [PubMed: 25460185]